Ichosia Biotechnology

Ichosia Biotechnology is developing a scalable method of mass-producing an enhanced red blood product, Erythrosyn, by leveraging proprietary genetic engineering techniques. Erythrosyn is created by genetically engineering human stem cells to transform into fully functioning red blood cell. By transitioning this natural erythropoietin process from the body into the laboratory, Erythrosyn is being designed to be producible on demand, universally compatible and more cost effective than donor blood.

网站

https://www.ichosia.com

Ichosia Biotechnology的外部链接

所属行业

生物技术

规模

2-10 人

总部

Worcester，Massachusetts

类型

私人持股

创立

2019